李登举_好大夫在线
1届年度好大夫

微信扫码关注医生

有问题随时问

综合推荐热度 5.0

在线服务满意度 99%

在线问诊量 3036

返回医生主页 门诊信息 患者投票 科普文章 患友咨询 心意礼物 患友会

李登举

主任医师 教授
返回医生主页 门诊信息 患者投票 科普文章 患友咨询 心意礼物 患友会

学术前沿

Novel Therapies for Relapsed ALL

发表者:李登举 人已读

The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monotherapy or in combination with chemotherapy improve the treatment of relapsed disease. For some ALL subsets, specifi c therapies are indicated.The addition of targeted therapy in Philadelphia chromosome–positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors. Nelarabine demonstrates华中科技大学同济医学院附属同济医院血液内科李登举
activity as monotherapy in T-cell ALL and is approved by the US Food and Drug Administration.Clofarabine, a second-generation purine analogue approved in pediatric leukemia, has shown activity in adult acute leukemias including ALL and acute myeloid leukemia. The role of pegaspargase in adult ALL requires further investigation. The benefi t of matched related-donor allogeneic stem cell transplantation is signifi cant for standard-risk ALL but not for high-risk ALL. Development of new drugs and agents tailored to subset-specific cytogeneticmolecular  characteristics remains vital to success in treating adult ALL.

问医生

与医生电话交流 开始

图文问诊开始

预约就诊
×
分享到微信
打开微信,点击底部的“发现”,
使用“扫一扫”即可在微信端打开网页进行分享。

发表于:2012-05-27 23:40

患者评价
  • 游** 2013-04-18 20:22:42

    白细胞低如何治疗

李登举大夫的信息

  • 感谢信: 0 感谢信 礼物: 0 礼物

李登举大夫电话咨询

李登举大夫已经开通电话咨询服务
直接与大夫本人通话,方便!快捷!

网上咨询李登举大夫

李登举的咨询范围: {14岁以上}。白血病,淋巴瘤骨髓瘤, 出血性疾病, 血栓性疾病。 更多>>

咨询李登举大夫